Navigation Links
Safinamide Phase III Study Results Presented at 2013 MDS Meeting
Date:6/18/2013

ence of treatment emergent abnormalities in laboratory results, ophthalmological examinations, vital signs and ECG was similar in all groups.

Analyses (On treatment, ANCOVA-LOCF) performed in the ITT population showed treatment with safinamide 50-100 mg/day significantly improved ON-Time without troublesome dyskinesia compared to placebo by 0.96 ± 0.21 hours (p<0.01) in the ITT. Significant benefits of safinamide 50-100 mg/day were also reported in OFF-time, Motor symptoms (UPDRS III), PDQ39, EQ-5D, clinical global impression of change and severity, and OFF-time post morning dose of levodopa.

The abstract presented at the MDS is available for download at: http://www.newron.com/ENG/Default.aspx?SEZ=5&PAG=122 and

http://http://www.zambonpharma.com

About safinamide

Safinamide, an alpha-aminoamide, is currently being developed by Newron as an add-on therapy to dopamine agonists or to levodopa in patients with early or mid- to late-stage Parkinson's disease (PD). It is believed to have both dopaminergic and non dopaminergic activities, including selective and reversible inhibition of monoamine oxidase B (MAO-B), activity-dependent sodium channel antagonism and inhibition of glutamate release in vitro.

About Newron Pharmaceuticals

Newron (SIX: NWRN) is a biopharmaceutical company focused on novel therapies for diseases of the Central Nervous System (CNS) and pain. The Company is headquartered in Bresso near Milan, Italy. Based on the phase III results of safinamide for treatment of Parkinson's disease, Newron is working to expedite the global filing of the compound, together with its partners. Zambon Group has the rights to commercialise safinamide globally, excluding Japan and other key Asian territories, and Meiji Seika'/>"/>

SOURCE Newron Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
2. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
3. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
4. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
5. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
6. Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimers Disease
7. NeuroDerm Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 International Congress of Parkinsons Disease and Movement Disorders
8. Epizyme Enrolls First Patient in Phase 1/2 Clinical Trial of EPZ-6438, an Inhibitor of EZH2
9. Generex Announces Interview of MD Andersons Dr. Elizabeth Mittendorf, Principal Investigator on Companys AE37 Phase IIb Breast Cancer Efficacy Trial
10. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
11. SanBio Announces FDA Clearance for the Initiation of a Phase I/2a Clinical Trial Testing Their Cell Therapy Product, SB623, in Patients with Traumatic Brain Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  Lannett Company, Inc. (NYSE: ... at the Canaccord Genuity 35th Annual Growth Conference on ... the InterContinental Boston Hotel.  A webcast ... .  Listeners are encouraged to visit the web site ... the presentation to register, download and install any necessary ...
(Date:7/30/2015)...  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) today ... at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) ... 2015 financial results and provide a corporate update. Arena ... Select Market closes that day. The conference ... callers and 914.495.8552 for international callers. Please specify to ...
(Date:7/30/2015)... Ohio, July 30, 2015  Cardinal Health today ... billion, an increase of 20 percent, and non-GAAP ... of $1.00, an increase of 20 percent. Non-GAAP ... On a GAAP basis, operating earnings increased 44 ... continuing operations increased 29 percent to $0.88. ...
Breaking Medicine Technology:Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 4Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 2Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 3Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 4Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 5Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 6Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 7Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 8Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 9Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 10Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 11Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 12Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 13Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 14Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 15Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 16Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 17Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 18Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 19Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 20Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 21Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 22Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 23Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 24Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 25Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 26Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 27Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 28Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 29Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 30Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 31Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 32Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 33
... DIEGO, May 4, 2011 Volcano Corporation (NASDAQ: ... precision guided therapy tools designed to enhance the treatment ... signing of a supply agreement with ev3, a Covidien ... Ultrasound ( IVUS) technology for use in ev3,s ...
... Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ... and gastroenterology markets, today announced first quarter 2011 financial results. ... ended March 31, 2011, net revenue was $10.7 million, up ... grew year-over-year despite a brief, planned halt in shipments of ...
Cached Medicine Technology:Volcano Corporation to Supply Intravascular Ultrasound Technology to Covidien for Integration with Plaque Excision Systems 2Volcano Corporation to Supply Intravascular Ultrasound Technology to Covidien for Integration with Plaque Excision Systems 3Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 2Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 3Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 4Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 5Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 6Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 7Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 8Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 9Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 10
(Date:7/30/2015)... Miami, FL (PRWEB) , ... July 30, 2015 , ... ... Florida, according to the Health News Florida on June 17th. Those untreated ... needle exchange programs to prevent the spread of dirty needles throughout the community. Ultimately ...
(Date:7/30/2015)... ... July 30, 2015 , ... Gummy smile surgeon, ... gum contouring and surgery, as well as the patented gum depigmentation treatmet. Dr. Farnoosh ... him popular with many patients from around the world. , “Like treatment of any ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... Mount Sinai Earns National Cancer Institute Designation , The Tisch Cancer Institute (TCI) ... National Cancer Institute (NCI)-designated cancer center. TCI joins an elite group of 69 ...
(Date:7/30/2015)... ... 30, 2015 , ... Bird B Gone, the leader in bird control products ... to repel pest birds from the AC units and ventilation systems on hospital roofs. ... even the West Nile virus. When these droppings dry, the fine powder can be ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... managers at multinational organizations and NGO’s, according to a new survey by leading ... shows that property damage and employee medical expenses represented the largest sources of ...
Breaking Medicine News(10 mins):Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6Health News:Bird B Gone’s New Bird Hazing System Keeps Disease-Carrying Bird Droppings Out of Hospitals 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 3
... localised prostate cancer, one of the more common cancers ... researchers at Sweden's Karolinska Institutet said. ... blood of a group of cancer patients and monitored ... was part of the Scandinavian Prostate Cancer Group collaboration. ...
... recent report has zeroed in on a potential threat to ... the influence of anti-allergy drugs. ,A survey ... that one in seven suffered from hayfever or other allergies ... ,Many of those questioned said they had ...
... smoking ban which began March 2004, has worked on many ... pollution, the health of bar workers has improved considerably. ... percent reduction in air pollution and an 80 percent cut ... published in the American Journal of Respiratory and Critical Care ...
... a Body Mass Index (BMI) of more than 30 than ... more likely, according to research published in the April issue ... figures for more than a thousand children over two decades ... but that levels were much more constant among teenagers included ...
... Safety study triggered decision to go beyond standard ... critical care experts at The Johns Hopkins Hospital ... hospital superbugs for every child admitted to its ... more stringent admission screening methods for methicillin-resistant Staphylococcus ...
... pentoxifylline appears to have limited benefit in the first-line ... according to a report in the April issue of ... a second report in the same issue finds that ... effective in patients with another ulcer-causing mouth disease, oral ...
Cached Medicine News:Health News:Method to Screen Prostate Cancer Less Effective 2Health News:Ireland’s Smoke Ban Seems To Do The Tric 2Health News:20-year Study Shows Significant Rise in Childhood Obesity, Especially Among Girls 2Health News:Johns Hopkins Begins Aggressive Screening for 'superbugs' in Children 2Health News:Johns Hopkins Begins Aggressive Screening for 'superbugs' in Children 3Health News:Clinical Studies Evaluate Potential Treatments for Mouth Ulcers 2Health News:Clinical Studies Evaluate Potential Treatments for Mouth Ulcers 3
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
... breadth of infectious disease ELISA products make ... standard assay protocols for faster integration into ... products provide increased reliability and run-to-run consistency. ... detection assays for a wide range of ...
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
Medicine Products: